• 1.西安醫(yī)科大學第一附屬醫(yī)院肝膽外科研究室(西安710061) 2.河南省舞鋼市人民醫(yī)院外科;

為探討膽囊癌患者的免疫狀態(tài)及其對結(jié)石在膽囊癌發(fā)病機理中的作用,采用散射濁光計免疫法檢測了單純膽囊癌、伴膽石膽囊癌、膽石癥患者和健康人的血清補體和免疫球蛋白水平,并采用雙抗體夾心ELISA法測定了上述各組血清T淋巴細胞亞群、膽汁和血清中的白細胞介素2(IL2)和可溶性白細胞介素2受體(sIL2R)的水平。結(jié)果顯示,單純膽囊癌及伴膽結(jié)石膽囊癌患者的細胞免疫受抑制,其CD+4細胞和IL2水平較正常對照組低,CD+8細胞和sIL2R水平明顯增高,且與膽囊癌的臨床分期相關(guān)。膽結(jié)石患者與伴膽結(jié)石膽囊癌相比,其CD+4細胞、IL2水平較高,CD+8細胞和sIL2R水平較低。本實驗結(jié)果提示:①膽囊癌患者處于免疫抑制狀態(tài);②在伴膽結(jié)石膽囊癌的發(fā)病過程中,膽結(jié)石作為一種慢性損傷和刺激,促使了CD+4、CD+8細胞之間的平衡及IL2及其受體之間的平衡失調(diào);③動態(tài)檢測T淋巴細胞及sIL2R水平可作為判斷膽囊癌病情有價值的參考指標。

引用本文: 焦興元,石景森,高金松,周連鎖. 膽囊癌患者細胞和體液免疫水平的測定及其臨床意義. 中國普外基礎(chǔ)與臨床雜志, 1999, 6(4): 227-229. doi: 復制

1. LissoniP,BamiS,RovelliF,etal.Thebiologicalsignificanceofsolubleinterleukin2receptorinsolidtumors.EurJCancer,1990;26(1)∶33.
2. LeeWJ,ChangKJ,LeeCS,etal.SelectdepressionofTlymphocytesubsetsingastriccancerpatients:animplicationofimmunotherapy.JSurgOncol,1994;55(3)∶165.
3. ZengZC,TangZY,LiuKD,etal.ObservationofchangesinperipheralTlymphocytesubsetsbyflowcytometryinpatientswithlivercancertreatedwithradioimmunotherapy.NucMedCommun,1995;16(5)∶378.
4. RebinLA,Nelson.Thesolubleinterleukin2receptor:biology,functionandclinicalapplication.AnnInternMed,1990;113(8)∶619.
5.  ButchAW,ChungCH.Cytokineexpressionbygerminalcentercells.JImmunol,1993;150(1)∶39.
6. LotzeMT,FinnOJ.Recentadvanceincellularimmunology:implicationsforimmunitytocancer.ImmunolToday,1990;11(4)∶190.
7.  石景森,周連鎖,王作仁等.830例肝外膽管癌的回顧性研究.中華外科雜志,1997;35(11)∶645.
8.  Rabeneck.Gallstoneandbileductcancer.Gastroenterology,1991;107(10)∶1205.
9. HensorDE,AlboresSavedraJ,CorleD.Carcinomaofthegallbladder:histologic;stageofdisease,gradeandsurvivedrates.Cancer,1992;70(11)∶1483.
  1. 1. LissoniP,BamiS,RovelliF,etal.Thebiologicalsignificanceofsolubleinterleukin2receptorinsolidtumors.EurJCancer,1990;26(1)∶33.
  2. 2. LeeWJ,ChangKJ,LeeCS,etal.SelectdepressionofTlymphocytesubsetsingastriccancerpatients:animplicationofimmunotherapy.JSurgOncol,1994;55(3)∶165.
  3. 3. ZengZC,TangZY,LiuKD,etal.ObservationofchangesinperipheralTlymphocytesubsetsbyflowcytometryinpatientswithlivercancertreatedwithradioimmunotherapy.NucMedCommun,1995;16(5)∶378.
  4. 4. RebinLA,Nelson.Thesolubleinterleukin2receptor:biology,functionandclinicalapplication.AnnInternMed,1990;113(8)∶619.
  5. 5.  ButchAW,ChungCH.Cytokineexpressionbygerminalcentercells.JImmunol,1993;150(1)∶39.
  6. 6. LotzeMT,FinnOJ.Recentadvanceincellularimmunology:implicationsforimmunitytocancer.ImmunolToday,1990;11(4)∶190.
  7. 7.  石景森,周連鎖,王作仁等.830例肝外膽管癌的回顧性研究.中華外科雜志,1997;35(11)∶645.
  8. 8.  Rabeneck.Gallstoneandbileductcancer.Gastroenterology,1991;107(10)∶1205.
  9. 9. HensorDE,AlboresSavedraJ,CorleD.Carcinomaofthegallbladder:histologic;stageofdisease,gradeandsurvivedrates.Cancer,1992;70(11)∶1483.